Bukwang Pharmaceutical Launches 'Erozet' for Dyslipidemia Treatment
Pitavastatin and Ezetimibe Combination
"Expanding the Cardiovascular Treatment Portfolio"
Bukwang Pharmaceutical announced on August 5 that it will launch "Erozet Tablets 1/10 mg (containing pitavastatin and ezetimibe)," a low-dose combination drug for dyslipidemia.
This product is used as an adjunct to diet to decrease elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-HDL cholesterol in patients with primary hypercholesterolemia (both heterozygous familial and non-familial) or mixed dyslipidemia, while increasing HDL-cholesterol (HDL-C).
Erojettab, a low-dose combination tablet for dyslipidemia. Bukwang Pharmaceuticals
View original imageBukwang Pharmaceutical has newly added a low-dose option to its existing pitavastatin and ezetimibe combination lineup. The company aims to fill the therapeutic gap between low- and high-dose statin monotherapy and to create a prescription environment that considers patient tolerability.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from Bukwang Pharmaceutical said, "We are now able to offer healthcare professionals and patients a more diverse and flexible range of prescription options in the dyslipidemia treatment field."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.